Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q3 FY25 Earnings Presentation
18 slides from Ngl Fine-chem's earnings presentation, Feb 10, 2025
Slide 1: Cover letter to stock exchanges for investor presentation
Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884,Website www.nglfinechem.com February 10, 2025 To, Listing Department, Listing Department, The BSE Lim
Slide 2: NGL Fine-Chem Limited Investor Presentation Q3 & 9MFY25
NGL Fine-Chem Limited INVESTOR PRESENTATION Q3 & 9MFY25
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 4: Inside This Presentation
Inside Pg. No. Pg. No. This Presentation 04 08 Q3 & 9M Overview, FY25 Key Strengths Highlights and Strategy Pg. No. 13 Historical Financial Performance
Slide 5: Q3 & 9MFY25 Highlights
01 Q3 & 9MFY25 Highlights 05 M A N A G E M E N T C O M M E N TA R Y 06 Q U A R T E R LY O P E R AT I O N A L M E T R I C S 07 S U M M A R Y O F P R O F I T A N D LO S S S TAT E M E N T 08 SUMMARY OF BAL ANCE SHEET 09 S U M M A R Y O F C A S H F LO W S TAT E M E N T
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, issues in African markets continue to I am pleased to provide an update on NGL exacerbate these challenges. Fine Chem Limited’s per formance for Q3 FY25. During this quar ter, we experienced a Despite the ongoing complexities, we remain decline in revenues, p
Slide 7: Operational Metrics
Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q3FY24 Q2FY25 Q3FY25 PARTICULARS Q3FY24 Q2FY25 Q3FY25 ANIMAL API 94% 94% 93% TOP 3 PRODUCTS 36% 38% 37% HUMAN API 2% 3% 2% TOP 5 PRODUCTS 51% 51% 50% INTERMEDIATES 2% 2% 2% TOP 10 PRODUCTS 72% 72% 72% FORMULATIONS 2% 2% 3% G
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ IN CRORES PARTICUL ARS Q3FY24 Q2FY25 Q3FY25 Q-o-Q Y-o-Y 9MFY24 9MFY25 Y-o-Y REVENUE FROM OPERATIONS 87.95 93.48 89.10 -4.69% 1.30% 239.23 273.34 14.26% OTHER INCOME 3.68 5.12 -0.13 -102.58% -103.58% 10.17 10.59 4.18% TOTAL INCOME 91.63 98.60 88.97 -9.77% -2.91%
Slide 9: Summary of Balance Sheet
Summary of Balance Sheet ₹ IN CRORES PARTICUL ARS FY24 H1FY25 SHAREHOLDERS FUND 262.63 280.29 NON CURRENT LIABILITIES 6.32 27.11 LONG TERM BORROWINGS 0.74 19.60 CURRENT LIABILITIES 86.59 88.45 SHORT TERM BORROWINGS 31.70 29.60 TOTAL EQUITY AND LIABILITIES 355.54 395.85 NON CURRENT ASSETS 142.87 160.
Slide 10: Summary of Cash Flow Statement
Summary of Cash Flow Statement ₹ IN CRORES PARTICUL ARS FY24 H1FY25 CASH FLOW FROM OPERATING ACTIVITIES 14.73 7.74 CASH FLOW FROM INVESTING ACTIVITIES (21.07) (1.05) CASH FLOW FROM FINANCING ACTIVITIES (1.08) (1.08) NET CASH FLOW (7.43) 5.60 CASH AT THE BEGINNING OF YEAR 7.83 0.40 CASH AT THE END OF
Slide 11: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 11 L E A D I N G A N I M A L H E A LT H C O M PA N Y 12 LEADERSHIP IN VETERINARY API SEGMENT 13 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA B I L I T I E S 14 S T R AT E G Y F O R N E X T L E G O F G R O W T H
Slide 12: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 33 APIs (31 Veterinary • Leadership in top • 3 state of the art • 50+ countries across • ~400 customers APIs, 2 Huma
Slide 13: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-house manufacturing and API SEGMENT ( ₹ I N CR O R E S ) 22% CAGR CONCENTRATION (OF SALES FY24) backward integrated facilities leading to cost competitiveness FY24 300 CUSTOMER PR
Slide 14: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 3 manufacturing facilities located at Tarapur & Navi 10,000 m 2 102 m 3 194 m 3 AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are
Slide 15: Strategy for next leg of growth
Strategy for next leg of growth BROWNFIELD EXPANSION • Completed expansion in ONGOING INITIATIVES subsidiary Macrotech TO INCREASE • Additional capacities of a CAPACITIES TO MEET intermediates GROWING DEMAND • Commercial production started GREENFIELD EXPANSION AT TARAPUR • 50% capacity expansion wit
Slide 16: Historical Financial Performance
03 Historical Financial Performance 16 ROBUST FINANCIAL PERFORMANCE
Slide 17: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES) FY24 339 FY24 53 FY24 41 FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 FY21 258 FY21 80 FY21 57 FY20 152 FY20 19 FY20 8 0 50 100 150 200 250 300 350 400 0 10 20 30 40 50 60 70 80 90 0 10 20 30 40 50 60 GROS
Slide 18: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Pallavi Pednekar Abhishek Mehra NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 301, E-square, Subhash Road, Vile Parle (East), Mumbai - 400057, M